Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus.

OBJECTIVES The aim of this study was assess serum ischemia modified albumin (IMA) in type 2 diabetes patients and determine its correlation with other risk factors for chronic complications such as inflammation and hyperglycemia. DESIGN AND METHODS Fasting glucose, glycated albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, uric acid, albumin, lactic acid, high-sensitivity C-reactive protein (hs-CRP) and IMA were measured in 80 patients with type 2 diabetes and 26 controls. RESULTS Fasting glucose, glycated albumin, triglycerides, creatinine, IMA and hs-CRP were significantly higher in patients with type 2 diabetes. Correlations were weak but significant between IMA and fasting glucose, IMA and hs-CRP, hs-CRP and HDL cholesterol and hs-CRP and fasting glucose were observed. CONCLUSIONS We have shown higher levels of IMA and hs-CRP in type 2 diabetes. Hyperglycemia and inflammation reduces the capacity of albumin to bind cobalt, resulting in higher IMA levels.

[1]  Qi Zhang,et al.  Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes , 2006, Cardiovascular diabetology.

[2]  D. Slone,et al.  The cobalt-albumin binding assay: insights into its mode of action. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[3]  R. Moresco,et al.  Evaluation of ischemia‐modified albumin in anemia associated to chronic kidney disease , 2008, Journal of clinical laboratory analysis.

[4]  D. Bar-Or,et al.  A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. , 2000, The Journal of emergency medicine.

[5]  D. Aronson.  Hyperglycemia and the pathobiology of diabetic complications. , 2008, Advances in cardiology.

[6]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[7]  H. Saito,et al.  Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. , 2009, Journal of atherosclerosis and thrombosis.

[8]  P. Collinson,et al.  Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin , 2005, Heart.

[9]  P O Collinson,et al.  Role of “Ischemia Modified Albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes , 2004, Emergency Medicine Journal.

[10]  K. Yamashita,et al.  Derivatives of reactive oxygen metabolites correlates with high-sensitivity C-reactive protein. , 2008, Journal of atherosclerosis and thrombosis.

[11]  J. Rocha,et al.  Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. , 2009, Clinical biochemistry.

[12]  J. Ordóñez‐Llanos,et al.  Ischemia-modified albumin during skeletal muscle ischemia. , 2004, Clinical chemistry.

[13]  A. Gönenç,et al.  Serum Cardiac Markers in Patients with Acute Myocardial Infarction: Oxidative Stress, C-Reactive Protein and N-Terminal Probrain Natriuretic Peptide , 2007, Journal of clinical biochemistry and nutrition.

[14]  H. Hirose,et al.  Relations between serum reactive oxygen metabolites (ROMs) and various inflammatory and metabolic parameters in a Japanese population. , 2009, Journal of atherosclerosis and thrombosis.

[15]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R. Hajjar,et al.  Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy , 2008, Nature Clinical Practice Cardiovascular Medicine.

[17]  P. Collinson,et al.  Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention , 2003, Circulation.

[18]  C. Palmeira,et al.  Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. , 2006, Toxicology and applied pharmacology.

[19]  G. Lippi,et al.  Evaluation of cardiac laboratory markers in patients with systemic sclerosis. , 2006, Clinical biochemistry.

[20]  S. Honda,et al.  Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. , 2003, Clinical chemistry.

[21]  G. Thomas,et al.  Plasma albumin cysteinylation is regulated by cystathionine β-synthase , 2004 .

[22]  Ann Marie Schmidt,et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.

[23]  R. Marfella,et al.  Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1 , 2002, Diabetologia.

[24]  Agnieszka Piwowar,et al.  Ischemia-Modified albumin level in type 2 diabetes mellitus—Preliminary report , 2008, Disease markers.

[25]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[26]  H. Shapiro,et al.  Low albumin level in the emergency department: a potential independent predictor of delayed mortality in blunt trauma. , 2003, The Journal of emergency medicine.

[27]  T. Sampietro,et al.  Increased Plasma C-Reactive Protein in Familial Hypoalphalipoproteinemia: A Proinflammatory Condition? , 2002, Circulation.

[28]  A. Vaag,et al.  Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People , 2008, Circulation.

[29]  High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity , 2004 .

[30]  P. Collinson,et al.  ISCHEMIA MODIFIED ALBUMIN , 2008 .

[31]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.